Serum CGRP in migraine patients using erenumab as preventive treatment

[1] Goadsby PJ(1993)Trigeminovascular System and Migraine: studies Characterizing Cerebrovascular and Neuropeptide Changes Seen in Humans and Cat Annals of neurology 33 48-56

[2] Edvinsson L(1990)Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache Annals of neurology 28 183-187

[3] Goadsby PJ(2013)Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine Neurology 81 1191-1196

[4] Edvinsson L(2010)Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura Cephalalgia 30 1179-1186

[5] Ekman R(2018)ARISE: A Phase 3 randomized trial of erenumab for episodic migraine Cephalalgia 38 1026-1037

[6] Cernuda-Morollón E(2018)Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial Cephalalgia 38 1442-1454

[7] Larrosa D(2018)Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study The Lancet 392 2280-2287

[8] Ramón C(2019)Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial The Lancet 394 1030-1040

[9] Vega J(2020)Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial The Lancet Neurology 19 814-825

[10] Martínez-Camblor P(2018)Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial JAMA 319 1999-2008

[1] Goadsby PJ(1993)Trigeminovascular System and Migraine: studies Characterizing Cerebrovascular and Neuropeptide Changes Seen in Humans and Cat Annals of neurology 33 48-56

[2] Edvinsson L(1990)Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache Annals of neurology 28 183-187

[3] Goadsby PJ(2013)Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine Neurology 81 1191-1196

[4] Edvinsson L(2010)Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura Cephalalgia 30 1179-1186

[5] Ekman R(2018)ARISE: A Phase 3 randomized trial of erenumab for episodic migraine Cephalalgia 38 1026-1037

[6] Cernuda-Morollón E(2018)Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial Cephalalgia 38 1442-1454

[7] Larrosa D(2018)Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study The Lancet 392 2280-2287

[8] Ramón C(2019)Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial The Lancet 394 1030-1040

[9] Vega J(2020)Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial The Lancet Neurology 19 814-825

[10] Martínez-Camblor P(2018)Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial JAMA 319 1999-2008